Back to search results

Ultrasound Effects on Glycemic Control in Type 2 Diabetes

This study is exploring if focused pulsed ultrasound, delivered to your liver and a nerve cluster in your abdomen using a General Electric LOGIQ E10 ultrasound machine, can help manage blood sugar levels in people with Type 2 Diabetes. You may be eligible if you are 21 to 75 years old, have had Type 2 Diabetes for at least three months, and are currently taking stable doses of certain oral diabetes medications like Metformin or Sulfonylureas. The main goal is to see if this ultrasound treatment causes any liver-related side effects, specifically changes in liver enzymes (AST/ALT) after two weeks. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design
This is an open-label, exploratory pilot study, meaning both you and the study team will know which treatment you are receiving. It plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your liver enzyme levels will be checked two weeks after the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05354947

Ultrasound Effects on Glycemic Control in T2DM

Recruiting
NAAges 21–75InterventionalTreatment
Yale University
~30 participants
Updated 2026-01-27 on ClinicalTrials.gov
What's tested:Ultrasound Delivery

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.
Measured over 2 weeks

Conditions

Type 2 Diabetes

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Raimund Herzog, MD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Alice Hahn
[email protected]
475-321-0504
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Metformin
Sulfonylureas
Meglitinides
Thiazolidinediones 4. HbA1c \> 7.0% and \< 10% by local laboratory analysis. 5. Body Mass Index (BMI) ≥ 18 to ≤ 40.0 kg/m2. 6. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Principal Investigator. 7. Female subjects must be non-pregnant and non-lactating and have a negative serum pregnancy test at screening and before the ultrasound session. 8. Ability to provide written informed consent.

What this trial measures

  • Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT.2 weeks

    Number of study participants who develop an elevation of liver transaminases compared to baseline parameters, including AST and ALT. Grade 1 delta ALT and / or AST \<3 x ULN; Grade 2 delta ALT and / or AST \>3 - 5 x ULN; Grade 3 delta ALT and / or AST \>5 - 20 x ULN; Grade 4 delta ALT and / or AST \>20 x ULN.